Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ERN1 | O75460 | 4/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | PADI4 | Q9UM07 | 1/20 | 0.37 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17488417 | 0.82 | ERN1 (0.53) | MAOAMAOBERN1TDP1KDM4E | |
| SCHEMBL28953244 | 0.82 | MAOA (0.52) | MAOAMAOBERN1TDP1KDM4E | |
| SCHEMBL23780919 | 0.82 | ERN1 (0.45) | MAOAMAOBERN1TDP1KDM4E | |
| SCHEMBL16651290 | 0.76 | CYP1A2 (0.47) | ERN1KDM4EMAPTRXFP1MEN1 | |
| SCHEMBL3042274 | 0.76 | ERN1 (0.61) | MAOAMAOBERN1TDP1KDM4E | |
| SCHEMBL6679033 | 0.76 | MAOA (0.70) | MAOAMAOBTDP1KDM4EMAPT | |
| SCHEMBL10474175 | 0.75 | RXRA (0.46) | ERN1KDM4ENPSR1RXFP1KMT2A | |
| SCHEMBL29175203 | 0.74 | MAOA (0.67) | MAOAMAOBTDP1KDM4EMAPT | |
| SCHEMBL29018850 | 0.73 | KMT2A (0.43) | MAOAMAOBERN1TDP1KDM4E | |
| SCHEMBL20957546 | 0.73 | ALDH1A1 (0.44) | KDM4ENPSR1MAPTRAB9ARXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7470713-B2 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-30 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232826-B2 | Tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2005082885-A1 | IMIDAZOLE BASED KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187218-A1 | Imidazole based kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2005-08-25 | — | — | US | disclosed |
| EP-1545529-A2 | NOVEL TYROSINE KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2005-06-29 | — | — | EP | disclosed |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-05-13 | — | — | US | disclosed |
| WO-2004030620-A2 | NOVEL TYROSINE KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187218-A1 | Imidazole based kinase inhibitors | MAP3K19, MAP3K1, ABL1 | MAOA 3150/4885MAOB 2141/4885ERN1 636/4885 |
| US-20040092514-A1 | Novel tyrosine kinase inhibitors | ABL1, ERBB2, ROS1 | MAOA 2361/4885MAOB 1854/4885ERN1 1092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.